En medio de la creciente demanda de energía limpia y sostenible, los científicos y los expertos en energía están explorando nuevas fronteras para aprovechar al máximo una de nuestras mayores fuentes de energía: el sol. Una idea innovadora ha surgido reciente …
Sanofi announced that its Q2 2023 Memorandum for modelling purposes is available on the “Investors” page of the company’s website:.
Press Release: Availability of the Q2 2023 Memorandum for modelling purposes Read More »
GSK plc announced that the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted in favor of recommending the use of AREXVY in adults aged 60 and older using shared clinical decision making.
AssayQuant® Technologies, Inc. introduces KinSight™ Kinome Profiling Services providing superior results including kinetic insights into selectivity and mechanisms of action for drug discovery.
Kinetic Insights with AssayQuant’s Fully Automated KinSight™ Kinome Profiling Services Read More »
Ferring Pharmaceuticals announced that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovative medicines by the US Food and Drug Administration.
Tagworks Pharmaceuticals BV announced a $65 million Series A financing led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures.
Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced that the first patient has been enrolled in a pivotal, multicenter U.S. Phase II/III trial of AntiBKV, MTx’s antibody therapeutic that targets BK polyomavirus infection in renal transplant patients.
BioCity Biopharma announced the initiation of a randomized, placebo-controlled Phase 2 clinical trial of its novel, oral endothelin A -receptor selective antagonist, SC0062, with the enrollment of two patients with IgA nephropathy (IgAN) in China (NCT05687890).
Masimo announced that Hospital La Fe in Valencia, Spain, is expanding its telehealth and telemonitoring program with the Masimo W1™ advanced health tracking watch.
Hospital La Fe Expands Telehealth Program with Masimo W1™ for Preoperative Patients Read More »
ValnevaSE, a specialty vaccine company, announced that its Supervisory Board has recommended a change of governance model.
